---
schema_version: "secwatch.filing_event.v1"
accession: "0001564590-21-040793"
form_type: "8-K"
ticker: "FATE"
cik: "0001434316"
company_name: "FATE THERAPEUTICS INC"
filed_at: "2021-08-04T23:59:59+00:00"
generated_at: "2026-06-29T22:29:56.199906+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Fate Therapeutics reports Q2 2021 results; first patient dosed with FT819 iPSC CAR T-cell therapy

## Summary
- Q2 2021 revenue $13.4M from collaborations; R&D expenses $48.0M; cash & investments $845.1M.
- First patient treated in Phase 1 trial of FT819, first-ever iPSC-derived CAR T-cell therapy, for ALL.
- FT516 interim data at ASCO: 8/11 patients (73%) objective response, 6 complete responses in B-cell lymphoma.
- FT538 Phase 1 in AML: 2 patients evaluable, 1 achieved CRi; dose escalation ongoing.
- Appointed Dr. Mark Plavsic as Chief Technical Officer and Dr. Yuan Xu to Board of Directors.

## SEC filing metadata
- accession: 0001564590-21-040793
- form_type: 8-K
- ticker: FATE
- cik: 0001434316
- company_name: FATE THERAPEUTICS INC
- filed_at: 2021-08-04T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1434316/000156459021040793/0001564590-21-040793-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1434316/000156459021040793/fate-8k_20210804.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001564590-21-040793
- JSON: https://secwatch.observer/filing/0001564590-21-040793.json
- Plain text: https://secwatch.observer/filing/0001564590-21-040793.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.